Epigenetic mechanisms in cancer formation and progression

Cancer Epigenetics: Biomolecular Therapeutics in Human Cancer

Volumn , Issue , 2011, Pages 253-298

  Fratta, Elisabetta ^a   Sigalotti, Luca ^a   Covre, Alessia ^a   Parisi, Giulia ^a   Danielli, Riccardo ^b   Jean, Hugues ^a,b   Nicolay, Marie ^a,b   Coral, Sandra ^a   Maio, Michele ^a,b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

DNA methylation in cancer, intense topics and histone methylation, methyl groups to side chain nitrogen atoms of arginine and lysine residues; Epigenetic alterations, role in initiation and progression of all cancer types; Epigenetic mechanisms in cancer formation and progression

Indexed keywords

EID: 84868492019     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118005743.ch10     Document Type: Chapter

References (360)

1. Antequera F, Bird A. (1999) CpG islands as genomic footprints of promoters that are associated with replication origins. Curr Biol; 9(17):R661-R667.
2. Klose RJ, Bird AP. (2006) Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci; 31(2): 89-97.
3. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, et al. (2007) Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol; 212(2): 330-344.
4. Egger G, Liang G, Aparicio A, Jones PA. (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature; 429(6990): 457-463.
5. Bird AP. (1986) CpG-rich islands and the function of DNA methylation. Nature; 321(6067): 209-213.
6. Barlow DP. (1995) Gametic imprinting in mammals. Science; 270(5242): 1610-1613.
7. Goto T, Monk M. (1998) Regulation of X-chromosome inactivation in development in mice and humans. Microbiol Mol Biol Rev; 62(2): 362-378.
8. Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H, et al. (2002) Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet; 31(2): 175-179.
9. Watt FM. (1998) Epidermal stem cells: markers, patterning and the control of stem cell fate. Philos Trans R Soc Lond B Biol Sci; 353(1370): 831-837.
10. Boyes J, Bird A. (1991) DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell; 64(6): 1123-1134.
11. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, et al. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet; 19(2): 187-191.
12. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. (1999) Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet; 23(1): 62-66.
13. Wade PA. (2001) Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene; 20(24): 3166-3173.
14. Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. (1999) Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev; 13(15): 1924-1935.
15. Kornberg RD. (1999) Eukaryotic transcriptional control. Trends Cell Biol; 9(12): M46-M49.
16. Jenuwein T, Allis CD. (2001) Translating the histone code. Science; 293(5532): 1074-1080.
17. Felsenfeld G, Groudine M. (2003) Controlling the double helix. Nature; 421(6921): 448-453.
18. Turner BM. (2002) Cellular memory and the histone code. Cell; 111(3): 285-291.
19. Strahl BD, Allis CD. (2000) The language of covalent histone modifications. Nature; 403(6765): 41-45.
20. Hashimshony T, Zhang J, Keshet I, Bustin M, Cedar H. (2003) The role of DNA methylation in setting up chromatin structure during development. Nat Genet; 34(2): 187-192.
21. Gronbaek K, Hother C, Jones PA. (2007) Epigenetic changes in cancer. APMIS; 115(10): 1039-1059.
22. Kanai Y, Hirohashi S. (2007) Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis; 28(12): 2434-2442.
23. Robertson KD. (2001) DNA methylation, methyltransferases, and cancer. Oncogene; 20(24): 3139-3155.
24. Jeltsch A. (2006) On the enzymatic properties of Dnmt1: specificity, processivity, mechanism of linear diffusion and allosteric regulation of the enzyme. Epigenetics; 1(2): 63-66.
25. Gowher H, Stockdale CJ, Goyal R, Ferreira H, Owen-Hughes T, Jeltsch A. (2005) De novo methylation of nucleosomal DNA by the mammalian Dnmt1 and Dnmt3A DNA methyltransferases. Biochemistry; 44(29): 9899-9904.
26. Liang G, Chan MF, Tomigahara Y, Tsai YC, Gonzales FA, Li E, et al. (2002) Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol; 22(2): 480-491.
27. Fuks F, Hurd PJ, Deplus R, Kouzarides T. (2003) The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res; 31(9): 2305-2312.
28. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. (2000) DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet; 25(3): 338-342.
29. Rountree MR, Bachman KE, Baylin SB. (2000) DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet; 25(3): 269-277.
30. Tatematsu KI, Yamazaki T, Ishikawa F. (2000) MBD2-MBD3 complex binds to hemi-methylated DNA and forms a complex containing DNMT1 at the replication foci in late S phase. Genes Cells; 5(8): 677-688.
31. Okano M, Bell DW, Haber DA, Li E. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell; 99(3): 247-257.
32. Fan H, Zhao ZJ, Cheng J, Su XW, Wu QX, Shan YF. (2009) Overexpression of DNA methyltransferase 1 and its biological significance in primary hepatocellular carcinoma. World J Gastroenterol; 15(16): 2020-2026.
33. Agoston AT, Argani P, Yegnasubramanian S, De Marzo AM, Ansari-Lari MA, Hicks JL, et al. (2005) Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem; 280(18): 18302-18310.
34. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. (2001) Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology; 33(3): 561-568.
35. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, et al. (2004) Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol; 164(2): 689-699.
36. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, et al. (1999) The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res; 27(11): 2291-2298.
37. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. (2002) Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci USA; 99(15): 10060-10065.
38. Feinberg AP, Vogelstein B. (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature; 301(5895): 89-92.
39. Feinberg AP. (1988) Alterations in DNA methylation in colorectal polyps and cancer. Prog Clin Biol Res; 279:309-317.
40. Suzuki K, Suzuki I, Leodolter A, Alonso S, Horiuchi S, Yamashita K, et al. (2006) Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell; 9(3): 199-207.
41. Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z, et al. (2008) Highresolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA; 105(1): 252-257.
42. Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC, et al. (2001) Genomewide hypomethylation in hepatocellular carcinogenesis. Cancer Res; 61(10): 4238-4243.
43. Jackson K, Yu MC, Arakawa K, Fiala E, Youn B, Fiegl H, et al. (2004) DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther; 3(12): 1225-1231.
44. Widschwendter M, Jiang G, Woods C, Muller HM, Fiegl H, Goebel G, et al. (2004) DNA hypomethylation and ovarian cancer biology. Cancer Res; 64(13): 4472-4480.
45. Ehrlich M. (2002) DNA methylation in cancer: too much, but also too little. Oncogene; 21(35): 5400-5413.
46. Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, et al. (2002) Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer; 35(1): 58-65.
47. Qu G, Dubeau L, Narayan A, Yu MC, Ehrlich M. (1999) Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat Res; 423(1-2):91-101.
48. Qu GZ, Grundy PE, Narayan A, Ehrlich M. (1999) Frequent hypomethylation in Wilms tumors of pericentromeric DNA in chromosomes 1 and 16. Cancer Genet Cytogenet; 109(1): 34-39.
49. Yeh A, Wei M, Golub SB, Yamashiro DJ, Murty VV, Tycko B. (2002) Chromosome arm 16q in Wilms tumors: unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene. Genes Chromosomes Cancer; 35(2): 156-163.
50. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, et al. (2008) A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst; 100(23): 1734-1738.
51. Pattamadilok J, Huapai N, Rattanatanyong P, Vasurattana A, Triratanachat S, Tresukosol D, et al. (2008) LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer; 18(4): 711-717.
52. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Calasanz MJ, et al. (2006) CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. Clin Cancer Res; 12(16): 4845-4850.
53. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Garate L, et al. (2006) Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia; 20(8): 1445-1448.
54. Bettstetter M, Woenckhaus M, Wild PJ, Rummele P, Blaszyk H, Hartmann A, et al. (2005) Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol; 205(5): 606-614.
55. Ogasawara S, Maesawa C, Yamamoto M, Akiyama Y, Wada K, Fujisawa K, et al. (2004) Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene; 23(5): 1117-1124.
56. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. (1993) bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood; 82(6): 1820-1828.
57. Watt PM, Kumar R, Kees UR. (2000) Promoter demethylation accompanies reactivation of the HOX11 proto-oncogene in leukemia. Genes Chromosomes Cancer; 29(4): 371-377.
58. Vachtenheim J, Horakova I, Novotna H. (1994) Hypomethylation of CCGG sites in the 3_ region of H-ras protooncogene is frequent and is associated with H-ras allele loss in non-small cell lung cancer. Cancer Res; 54(5): 1145-1148.
59. Oshimo Y, Nakayama H, Ito R, Kitadai Y, Yoshida K, Chayama K, et al. (2003) Promoter methylation of cyclin D2 gene in gastric carcinoma. Int J Oncol; 23(6): 1663-1670.
60. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, et al. (2003) Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res; 63(14): 4158-4166.
61. Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J. (2003) Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res; 63(3): 664-673.
62. Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C, et al. (2005) Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res; 65(17): 7635-7643.
63. Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani SA. (2002) Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J Biol Chem; 277(44): 41571-41579.
64. Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T, et al. (2005) Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res; 11(16): 5793-5801.
65. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC. (2005) P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res; 11(16): 5869-5877.
66. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev; 188:22-32.
67. Scanlan MJ, Simpson AJ, Old LJ. (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun; 4:1.
68. Zendman AJ, Ruiter DJ, van Muijen GN. (2003) Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol; 194(3): 272-288.
69. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L. (2003) Epigenetic targets for immune intervention in human malignancies. Oncogene; 22(42): 6484-6488.
70. Calabro L, Fonsatti E, Altomonte M, Pezzani L, Colizzi F, Nanni P, et al. (2005) Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. J Cell Physiol; 202(2): 474-477.
71. Gattei V, Fonsatti E, Sigalotti L, Degan M, Di Giacomo AM, Altomonte M, et al. (2005) Epigenetic immunomodulation of hematopoietic malignancies. Semin Oncol; 32(5): 503-510.
72. Barker PA, Salehi A. (2002) The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res; 67(6): 705-712.
73. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, et al. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med; 187(2): 265-270.
74. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, et al. (2007) Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res; 13(21): 6386-6395.
75. Brichard VG, Lejeune D. (2007) GSK’s antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine; 25(Suppl 2):B61-B71.
76. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, et al. (2007) Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA; 104(31): 12837-12842.
77. Qu GZ, Ehrlich M. (1999) Demethylation and expression of methylated plasmid DNA stably transfected into HeLa cells. Nucleic Acids Res; 27(11): 2332-2338.
78. Herman JG, Baylin SB. (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med; 349(21): 2042-2054.
79. Jones PA. (2002) DNA methylation and cancer. Oncogene; 21(35): 5358-5360.
80. Knudson AG. (1996) Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol; 122(3): 135-140.
81. Jones PA, Laird PW. (1999) Cancer epigenetics comes of age. Nat Genet; 21(2): 163-167.
82. Ohtani-Fujita N, Dryja TP, Rapaport JM, Fujita T, Matsumura S, Ozasa K, et al. (1997) Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma. Cancer Genet Cytogenet; 98(1): 43-49.
83. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, et al. (1997) Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet; 60(4): 765-771.
84. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA; 95(12): 6870-6875.
85. Baylin SB, Belinsky SA, Herman JG. (2000) Aberrant methylation of gene promoters in cancer-concepts, misconcepts, and promise. J Natl Cancer Inst; 92(18): 1460-1461.
86. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. (1991) Allelespecific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet; 48(5): 880-888.
87. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, et al. (2000) Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res; 60(1): 129-133.
88. Robertson KD, Jones PA. (1998) The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and downregulated by wild-type p53. Mol Cell Biol; 18(11): 6457-6473.
89. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res; 57(5): 837-841.
90. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. (1995) 5_ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med; 1(7): 686-692.
91. Galm O, Yoshikawa H, EstellerM, Osieka R, Herman JG. (2003) SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood; 101(7): 2784-2788.
92. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al. (2001) SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet; 28(1): 29-35.
93. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. (2003) SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA; 100(24): 14133-14138.
94. Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, et al. (2004) Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res; 10(23): 7917-7924.
95. Guo M, House MG, Akiyama Y, Qi Y, Capagna D, Harmon J, et al. (2006) Hypermethylation of the GATA gene family in esophageal cancer. Int J Cancer; 119(9): 2078-2083.
96. Wakana K, Akiyama Y, Aso T, Yuasa Y. (2006) Involvement of GATA-4/-5 transcription factors in ovarian carcinogenesis. Cancer Lett; 241(2): 281-288.
97. Kang GH, Lee S, Lee HJ, Hwang KS. (2004) Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol; 202(2): 233-240.
98. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. (2000) Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res; 60(16): 4366-4371.
99. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA; 91(21): 9700-9704.
100. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, et al. (1998) Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res; 58(23): 5310-5314.
101. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. (1995) Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res; 55(11): 2279-2283.
102. Sasaki M, Dharia A, Oh BR, Tanaka Y, Fujimoto S, Dahiya R. (2001) Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res; 61(1): 97-102.
103. Bovenzi V, Le NL, Cote S, Sinnett D, Momparler LF, Momparler RL. (1999) DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2_-deoxycytidine. Anticancer Drugs; 10(5): 471-476.
104. Cote S, Sinnett D, Momparler RL. (1998) Demethylation by 5-aza-2_-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs; 9(9): 743-750.
105. Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R, et al. (2004) Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res; 10(11): 3825-3830.
106. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, et al. (2000) Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst; 92(16): 1303-1307.
107. Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, et al. (2003) Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res; 63(9): 2316-2321.
108. Chu LC, Eberhart CG, Grossman SA, Herman JG. (2006) Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer; 119(10): 2487-2491.
109. Esteller M, Guo M, Moreno V, Peinado MA, Capella G, Galm O, et al. (2002) Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res; 62(20): 5902-5905.
110. Jeronimo C, Henrique R, Oliveira J, Lobo F, Pais I, Teixeira MR, et al. (2004) Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. J Clin Pathol; 57(8): 872-876.
111. Kwong J, Lo KW, Chow LS, To KF, Choy KW, Chan FL, et al. (2005) Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma. Neoplasia; 7(1): 67-74.
112. Pfeifer GP, Dammann R. (2005) Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc); 70(5): 576-583.
113. Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, et al. (2002) Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett; 176(2): 149-158.
114. Tomii K, Tsukuda K, Toyooka S, Dote H, Hanafusa T, Asano H, et al. (2007) Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer; 120(3): 566-573.
115. Chan KY, Ozcelik H, Cheung AN, Ngan HY, Khoo US. (2002) Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res; 62(14): 4151-4156.
116. Dobrovic A, Simpfendorfer D. (1997) Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res; 57(16): 3347-3350.
117. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. (1998) MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene; 17(18): 2413-2417.
118. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, et al. (1999) Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res; 59(5): 1090-1095.
119. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res; 59(4): 793-797.
120. Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF, et al. (2006) Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci USA; 103(23): 8822-8827.
121. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, et al. (2000) Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst; 92(18): 1511-1516.
122. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, et al. (2002) Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res; 8(2): 464-470.
123. Dong SM, Kim HS, Rha SH, Sidransky D. (2001) Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res; 7(7): 1982-1986.
124. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. (2001) CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res; 61(7): 2847-2851.
125. Katzenellenbogen RA, Baylin SB, Herman JG. (1999) Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood; 93(12): 4347-4353.
126. Kissil JL, Feinstein E, Cohen O, Jones PA, Tsai YC, Knowles MA, et al. (1997) DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene; 15(4): 403-407.
127. Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, et al. (2001) Promoter hypermethylation patterns of p16, O6-methylguanine-DNAmethyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res; 61(3): 939-942.
128. Schneider-Stock R, Kuester D, Ullrich O, Mittag F, Habold C, Boltze C, et al. (2006) Close localization of DAP-kinase positive tumour-associated macrophages and apoptotic colorectal cancer cells. J Pathol; 209(1): 95-105.
129. Simpson DJ, Clayton RN, Farrell WE. (2002) Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene; 21(8): 1217-1224.
130. Wong TS, Chang HW, Tang KC, Wei WI, Kwong DL, Sham JS, et al. (2002) High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. Clin Cancer Res; 8(2): 433-437.
131. Chim CS, Liang R, Fung TK, Choi CL, Kwong YL. (2007) Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol; 60(6): 664-669.
132. Christoph F, Kempkensteffen C, Weikert S, Kollermann J, Krause H, Miller K, et al. (2006) Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer; 95(12): 1701-1707.
133. Fu WN, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC, et al. (2003) Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene; 22(3): 451-455.
134. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, et al. (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature; 409(6817): 207-211.
135. Akahira J, Sugihashi Y, Ito K, Niikura H, Okamura K, Yaegashi N. (2004) Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer. Cancer Sci; 95(1): 40-43.
136. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM. (2000) TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res; 60(22): 6236-6242.
137. Guan X, Sagara J, Yokoyama T, Koganehira Y, Oguchi M, Saida T, et al. (2003) ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma. Int J Cancer; 107(2): 202-208.
138. Moriai R, Tsuji N, Kobayashi D, Yagihashi A, Namiki Y, Takahashi H, et al. (2002) A proapoptotic caspase recruitment domain protein gene, TMS1, is hypermethylated in human breast and gastric cancers. Anticancer Res; 22(6C):4163-4168.
139. Stone AR, Bobo W, Brat DJ, Devi NS, Van Meir EG, Vertino PM. (2004) Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol; 165(4): 1151-1161.
140. Virmani A, Rathi A, Sugio K, Sathyanarayana UG, Toyooka S, Kischel FC, et al. (2003) Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer. Int J Cancer; 106(2): 198-204.
141. Zhang C, Li H, Zhou G, Zhang Q, Zhang T, Li J, et al. (2007) Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells. J Pathol; 212(2): 134-142.
142. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, et al. (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA; 91(24): 11733-11737.
143. Jhaveri MS, Morrow CS. (1998) Methylation-mediated regulation of the glutathione S-transferase P1 gene in human breast cancer cells. Gene; 210(1): 1-7.
144. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG. (2000) E-cadherin expression is silenced by 5_ CpG island methylation in acute leukemia. Clin Cancer Res; 6(11): 4243-4248.
145. Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, et al. (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet; 26(1): 16-17.
146. Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L, et al. (1998) Mechanisms of inactivation of E-cadherin in breast cancer cell lines. Cancer Res; 58(9): 1972-1977.
147. Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI, Shridhar V. (1999) Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol; 15(4): 715-720.
148. Sato M, Mori Y, Sakurada A, Fujimura S, Horii A. (1998) The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet; 103(1): 96-101.
149. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, et al. (2001) Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res; 61(11): 4556-4560.
150. Toyooka S, Toyooka KO, Harada K, Miyajima K, Makarla P, Sathyanarayana UG, et al. (2002) Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Res; 62(12): 3382-3386.
151. Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH. (2004) Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest; 84(7): 884-893.
152. Li Q, Ahuja N, Burger PC, Issa JP. (1999) Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene; 18(21): 3284-3289.
153. Oue N, Matsumura S, Nakayama H, Kitadai Y, Taniyama K, Matsusaki K, et al. (2003) Reduced expression of the TSP1 gene and its association with promoter hypermethylation in gastric carcinoma. Oncology; 64(4): 423-429.
154. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al. (2000) Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res; 60(7): 1835-1839.
155. Nie Y, Yang G, Song Y, Zhao X, So C, Liao J, et al. (2001) DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis; 22(10): 1615-1623.
156. Feinberg AP, Ohlsson R, Henikoff S. (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet; 7(1): 21-33.
157. Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M, et al. (2007) Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci; 12:4254-4266.
158. Baylin SB, Ohm JE. (2006) Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer; 6(2):107-116.
159. Putzi MJ, De Marzo AM. (2000) Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology; 56(5): 828-832.
160. Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, et al. (1999) Regulation of JNK signaling by GSTp. EMBO J; 18(5): 1321-1334.
161. Xia C, Hu J, Ketterer B, Taylor JB. (1996) The organization of the human GSTP1-1 gene promoter and its response to retinoic acid and cellular redox status. Biochem J; 313(Pt 1):155-161.
162. Hayes JD, Pulford DJ. (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol; 30(6): 445-600.
163. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, et al. (2003) Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol; 163(3): 923-933.
164. Li LC, Okino ST, Dahiya R. (2004) DNA methylation in prostate cancer. Biochim Biophys Acta; 1704(2): 87-102.
165. Nakayama T, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H, Ito H, et al. (2001) The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Invest; 81(7): 1049-1057.
166. Li LC, Zhao H, Nakajima K, Oh BR, Ribeiro Filho LA, Carroll P, et al. (2001) Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol; 166(2): 705-709.
167. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet; 25(3): 315-319.
168. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, et al. (2001) Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene; 20(12): 1509-1518.
169. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, et al. (2001) The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA; 98(13): 7504-7509.
170. Catteau A, Morris JR. (2002) BRCA1 methylation: a significant role in tumour development? Semin Cancer Biol; 12(5):359-371.
171. Esteller M. (2000) Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer; 36(18): 2294-2300.
172. Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, et al. (2007) Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci; 81(4): 280-287.
173. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, et al. (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst; 93(9): 691-699.
174. Hayashi H, Yazawa T, Okudela K, Nagai J, Ito T, Kanisawa M, et al. (2002) Inactivation of O6-methylguanine-DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers. Jpn J Cancer Res; 93(2): 184-189.
175. Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, et al. (2001) p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res; 61(8): 3419-3424.
176. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res; 59(1): 67-70.
177. Paluszczak J, Baer-Dubowska W. (2006) Epigenetic diagnostics of cancer-the application of DNA methylation markers. J Appl Genet; 47(4): 365-375.
178. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med; 343(19): 1350-1354.
179. Reik W, Walter J. (1998) Imprinting mechanisms in mammals. Curr Opin Genet Dev; 8(2): 154-164.
180. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, et al. (1993) Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms’ tumour. Nature; 362(6422): 749-751.
181. Zhan S, Shapiro DN, Helman LJ. (1994) Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest; 94(1): 445-448.
182. Rainier S, Dobry CJ, Feinberg AP. (1995) Loss of imprinting in hepatoblastoma. Cancer Res; 55(9): 1836-1838.
183. Elkin M, Shevelev A, Schulze E, Tykocinsky M, Cooper M, Ariel I, et al. (1995) The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma. FEBS Lett; 374(1): 57-61.
184. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. (1998) Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med; 4(11): 1276-1280.
185. Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T, et al. (1995) Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene; 10(6): 1193-1198.
186. Kim HT, Choi BH, Niikawa N, Lee TS, Chang SI. (1998) Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors. Am J Med Genet; 80(4): 391-395.
187. Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, et al. (1998) Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood; 91(9): 3144-3147.
188. Leighton PA, Saam JR, Ingram RS, Stewart CL, Tilghman SM. (1995) An enhancer deletion affects both H19 and Igf2 expression. Genes Dev; 9(17): 2079-2089.
189. Thorvaldsen JL, Duran KL, Bartolomei MS. (1998) Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev; 12(23): 3693-3702.
190. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. (2000) CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature; 405(6785): 486-489.
191. Takai D, Gonzales FA, Tsai YC, Thayer MJ, Jones PA. (2001) Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet; 10(23): 2619-2626.
192. Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, et al. (2001) Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst; 93(22): 1698-1703.
193. Frevel MA, Sowerby SJ, Petersen GB, Reeve AE. (1999) Methylation sequencing analysis refines the region of H19 epimutation in Wilms tumor. J Biol Chem; 274(41): 29331-29340.
194. Vu TH, Li T, Nguyen D, Nguyen BT, Yao XM, Hu JF, et al. (2000) Symmetric and asymmetric DNA methylation in the human IGF2-H19 imprinted region. Genomics; 64(2): 132-143.
195. Cui H, Hedborg F, He L, Nordenskjold A, Sandstedt B, Pfeifer-Ohlsson S, et al. (1997) Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms’ tumorigenesis. Cancer Res; 57(20): 4469-4473.
196. Okamoto K, Morison IM, Taniguchi T, Reeve AE. (1997) Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proc Natl Acad Sci USA; 94(10): 5367-5371.
197. Kobayashi S, Kohda T, Miyoshi N, Kuroiwa Y, Aisaka K, Tsutsumi O, et al. (1997) Human PEG1/MEST, an imprinted gene on chromosome 7. Hum Mol Genet; 6(5): 781-786.
198. Pedersen IS, Dervan PA, Broderick D, Harrison M, Miller N, Delany E, et al. (1999) Frequent loss of imprinting of PEG1/MEST in invasive breast cancer. Cancer Res; 59(21): 5449-5451.
199. Kohda M, Hoshiya H, Katoh M, Tanaka I, Masuda R, Takemura T, et al. (2001) Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Mol Carcinog; 31(4): 184-191.
200. Thompson JS, Reese KJ, DeBaun MR, Perlman EJ, Feinberg AP. (1996) Reduced expression of the cyclin-dependent kinase inhibitor gene p57KIP2 in Wilms’ tumor. Cancer Res; 56(24): 5723-5727.
201. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, et al. (2003) Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res; 63(14): 4174-4180.
202. Santos-Rosa H, Caldas C. (2005) Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer; 41(16): 2381-2402.
203. Tschiersch B, Hofmann A, Krauss V, Dorn R, Korge G, Reuter G. (1994) The protein encoded by the Drosophila position-effect variegation suppressor gene Su(var)3-9 combines domains of antagonistic regulators of homeotic gene complexes. EMBO J; 13(16): 3822-3831.
204. Jones RS, Gelbart WM. (1993) The Drosophila Polycomb-group gene Enhancer of zeste contains a region with sequence similarity to trithorax. Mol Cell Biol; 13(10): 6357-6366.
205. Stassen MJ, Bailey D, Nelson S, Chinwalla V, Harte PJ. (1995) The Drosophila trithorax proteins contain a novel variant of the nuclear receptor type DNA binding domain and an ancient conserved motif found in other chromosomal proteins. Mech Dev; 52(2-3):209-223.
206. Lund AH, van LM. (2004) Epigenetics and cancer. Genes Dev; 18(19): 2315-2335.
207. Rea S, Eisenhaber F, O’Carroll D, Strahl BD, Sun ZW, Schmid M, et al. (2000) Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature; 406(6796): 593-599.
208. Bannister AJ, Miska EA. (2000) Regulation of gene expression by transcription factor acetylation. Cell Mol Life Sci; 57(8-9):1184-1192.
209. Lachner M, O’Carroll D, Rea S, Mechtler K, Jenuwein T. (2001) Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature; 410(6824): 116-120.
210. Peters AH, Mermoud JE, O’Carroll D, Pagani M, Schweizer D, Brockdorff N, et al. (2002) Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nat Genet; 30(1): 77-80.
211. Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O’Carroll D, et al. (2001) Rb targets histone H3 methylation and HP1 to promoters. Nature; 412(6846): 561-565.
212. Owa T, Yoshino H, Yoshimatsu K, Nagasu T. (2001) Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem; 8(12): 1487-1503.
213. Lakshmikuttyamma A, Takahashi N, Pastural E, Torlakovic E, Amin HM, Garcia-Manero G, et al. (2009) RIZ1 is potential CML tumor suppressor that is downregulated during disease progression. J Hematol Oncol; 2:28.
214. Buyse IM, Takahashi EI, Huang S. (1996) Physical mapping of the retinoblastoma interacting zinc finger gene RIZ to D1S228 on chromosome 1p36. Genomics; 34(1): 119-121.
215. White PS, Sulman EP, Porter CJ, Matise TC. (1999) A comprehensive view of human chromosome 1. Genome Res; 9(10): 978-988.
216. Fang W, Piao Z, Simon D, Sheu JC, Huang S. (2000) Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13-p36.23 and mutational analysis of the RIZ (PRDM2) gene localized to the region. Genes Chromosomes Cancer; 28(3): 269-275.
217. Sakurada K, Furukawa T, Kato Y, Kayama T, Huang S, Horii A. (2001) RIZ, the retinoblastoma protein interacting zinc finger gene, is mutated in genetically unstable cancers of the pancreas, stomach, and colorectum. Genes Chromosomes Cancer; 30(2): 207-211.
218. Piao Z, Fang W, Malkhosyan S, Kim H, Horii A, Perucho M, et al. (2000) Frequent frameshift mutations of RIZ in sporadic gastrointestinal and endometrial carcinomas with microsatellite instability. Cancer Res; 60(17): 4701-4704.
219. Chadwick RB, Jiang GL, Bennington GA, Yuan B, Johnson CK, Stevens MW, et al. (2000) Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc Natl Acad Sci USA; 97(6): 2662-2667.
220. He L, Yu JX, Liu L, Buyse IM, Wang MS, Yang QC, et al. (1998) RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res; 58(19): 4238-4244.
221. Liu L, Shao G, Steele-Perkins G, Huang S. (1997) The retinoblastoma interacting zinc finger gene RIZ produces a PR domain-lacking product through an internal promoter. J Biol Chem; 272(5): 2984-2991.
222. Steele-Perkins G, Fang W, Yang XH, Van GM, Carling T, Gu J, et al. (2001) Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev; 15(17): 2250-2262.
223. Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G. (1996) Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA; 93(4): 1642-1647.
224. Brooks DJ, Woodward S, Thompson FH, Dos SB, Russell M, Yang JM, et al. (1996) Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer; 74(10): 1518-1525.
225. Schneider R, Bannister AJ, Kouzarides T. (2002) Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci; 27(8): 396-402.
226. Wang X, Yeh S, Wu G, Hsu CL, Wang L, Chiang T, et al. (2001) Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells. J Biol Chem; 276(44): 40417-40423.
227. Jaju RJ, Fidler C, Haas OA, Strickson AJ, Watkins F, Clark K, et al. (2001) A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood; 98(4): 1264-1267.
228. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. (2000) Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res; 60(15): 4058-4061.
229. Angrand PO, Apiou F, Stewart AF, Dutrillaux B, Losson R, Chambon P. (2001) NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics; 74(1): 79-88.
230. Rosati R, La SR, Veronese A, Aventin A, Schwienbacher C, Vallespi T, et al. (2002) NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood; 99(10): 3857-3860.
231. Francis NJ, Kingston RE. (2001) Mechanisms of transcriptional memory. Nat Rev Mol Cell Biol; 2(6): 409-421.
232. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. (2007) Genome regulation by polycomb and trithorax proteins. Cell; 128(4): 735-745.
233. Simon J, Chiang A, Bender W, Shimell MJ, O’Connor M. (1993) Elements of the Drosophila bithorax complex that mediate repression by Polycomb group products. Dev Biol; 158(1): 131-144.
234. Ringrose L, Paro R. (2004) Epigenetic regulation of cellular memory by the polycomb and trithorax group proteins. Annu Rev Genet; 38:413-443.
235. Otte AP, Kwaks TH. (2003) Gene repression by Polycomb group protein complexes: a distinct complex for every occasion? Curr Opin Genet Dev; 13(5):448-454.
236. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. (2002) Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev; 16(22): 2893-2905.
237. Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, et al. (2002) Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell; 111(2): 197-208.
238. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature; 419(6907): 624-629.
239. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA; 100(20): 11606-11611.
240. Raaphorst FM, Meijer CJ, Fieret E, Blokzijl T, Mommers E, Buerger H, et al. (2003) Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia; 5(6): 481-488.
241. Chen H, Tu SW, Hsieh JT. (2005) Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem; 280(23): 22437-22444.
242. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, Ergenekon E. (2005) Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int; 75(3): 252-257.
243. Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, Miller K, et al. (2005) Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med; 16(2): 349-353.
244. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol; 24(2): 268-273.
245. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. (2006) Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci; 97(6): 484-491.
246. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H, et al. (2005) Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer; 92(9): 1754-1758.
247. Mattioli E, Vogiatzi P, Sun A, Abbadessa G, Angeloni G, D’Ugo D, et al. (2007) Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol; 210(1): 183-191.
248. Merola E, Mattioli E, Minimo C, Zuo W, Rabitti C, Cicala M, et al. (2006) Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett’s esophagus. J Cell Physiol; 207(2): 512-519.
249. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. (1991) Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell; 65(5): 753-763.
250. van LM, Verbeek S, Scheijen B, Wientjens E, van der GH, Berns A. (1991) Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell; 65(5): 737-752.
251. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van LM. (1999) The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature; 397(6715): 164-168.
252. Sherr CJ. (2001) The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol; 2(10): 731-737.
253. Silva J, Garcia V, Garcia JM, Pena C, Dominguez G, Diaz R, et al. (2007) Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res; 9(4):R55.
254. Chan CS, Rastelli L, Pirrotta V. (1994) A Polycomb response element in the Ubx gene that determines an epigenetically inherited state of repression. EMBO J; 13(11): 2553-2564.
255. Mohrmann L, Verrijzer CP. (2005) Composition and functional specificity of SWI2/SNF2 class chromatin remodeling complexes. Biochim Biophys Acta; 1681(2-3):59-73.
256. Peterson CL. (2003) Transcriptional activation: getting a grip on condensed chromatin. Curr Biol; 13(5):R195-R197.
257. Reisman D, Glaros S, Thompson EA. (2009) The SWI/SNF complex and cancer. Oncogene; 9:28(14):1653-1668.
258. Phelan ML, Sif S, Narlikar GJ, Kingston RE. (1999) Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell; 3(2): 247-253.
259. Ichinose H, Garnier JM, Chambon P, Losson R. (1997) Ligand-dependent interaction between the estrogen receptor and the human homologues of SWI2/SNF2. Gene; 188(1): 95-100.
260. Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, et al. (1994) The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell; 79(1): 119-130.
261. Cheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV. (1999) c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet; 22(1): 102-105.
262. Trouche D, Le Chalony C, Muchardt C, Yaniv M, Kouzarides T. (1997) RB and hbrm cooperate to repress the activation functions of E2F1. Proc Natl Acad Sci USA; 94(21): 11268-11273.
263. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE. (2003) Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res; 63(3): 560-566.
264. Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W, Weissman BE. (2001) Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol; 186(1): 136-145.
265. Wong AK, Shanahan F, Chen Y, Lian L, Ha P, Hendricks K, et al. (2000) BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res; 60(21): 6171-6177.
266. Sevenet N, Lellouch-Tubiana A, Schofield D, Hoang-Xuan K, Gessler M, Birnbaum D, et al. (1999) Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet; 8(13): 2359-2368.
267. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, et al. (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature; 394(6689): 203-206.
268. Zhang ZK, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, et al. (2002) Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol; 22(16): 5975-5988.
269. Oruetxebarria I, Venturini F, Kekarainen T, Houweling A, Zuijderduijn LM, Mohd-Sarip A, et al. (2004) P16INK4a is required for hSNF5 chromatin remodelerinduced cellular senescence in malignant rhabdoid tumor cells. J Biol Chem; 279(5): 3807-3816.
270. Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani E, et al. (2005) Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci USA; 102(24): 8603-8608.
271. Tyagi S, Chabes AL,Wysocka J, HerrW. (2007) E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell; 27(1): 107-119.
272. Ayton PM, Cleary ML. (2001) Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene; 20(40): 5695-5707.
273. Krivtsov AV, Armstrong SA. (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer; 7(11): 823-833.
274. Grunstein M. (1997) Histone acetylation in chromatin structure and transcription. Nature; 389(6649): 349-352.
275. Iizuka M, Smith MM. (2003) Functional consequences of histone modifications. Curr Opin Genet Dev; 13(2): 154-160.
276. Wang GG, Cai L, Pasillas MP, Kamps MP. (2007) NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol; 9(7): 804-812.
277. Inche AG, La Thangue NB. (2006) Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov Today; 11(3-4):97-109.
278. Marks PA, Richon VM, Breslow R, Rifkind RA. (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol; 13(6): 477-483.
279. Squatrito M, Gorrini C, Amati B. (2006) Tip60 in DNA damage response and growth control: many tricks in one HAT. Trends Cell Biol; 16(9): 433-442.
280. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, et al. (2006) Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell; 24(6): 841-851.
281. Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L, et al. (2007) Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature; 448(7157): 1063-1067.
282. Iyer NG, Ozdag H, Caldas C. (2004) p300/CBP and cancer. Oncogene; 23(24): 4225-4231.
283. Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ. (2008) Adenovirus small e1a alters global patterns of histone modification. Science; 321(5892): 1084-1085.
284. Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK. (2008) Epigenetic reprogramming by adenovirus e1a. Science; 321(5892): 1086-1088.
285. Yang XJ. (2004) The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res; 32(3): 959-976.
286. Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, et al. (1997) Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood; 90(12): 4699-4704.
287. Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, et al. (1997) MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA; 94(16): 8732-8737.
288. Panagopoulos I, Isaksson M, Lindvall C, Bjorkholm M, Ahlgren T, Fioretos T, et al. (2000) RT-PCR analysis of the MOZ-CBP and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13). Genes Chromosomes Cancer; 28(4): 415-424.
289. Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, et al. (1996) The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet; 14(1): 33-41.
290. Chan EM, Chan RJ, Comer EM, Goulet RJ III, Crean CD, Brown ZD, et al. (2007) MOZ and MOZ-CBP cooperate with NF-kappaB to activate transcription from NF-kappaB-dependent promoters. Exp Hematol; 35(12): 1782-1792.
291. Champagne N, Bertos NR, Pelletier N, Wang AH, Vezmar M, Yang Y, et al. (1999) Identification of a human histone acetyltransferase related to monocytic leukemia zinc finger protein. J Biol Chem; 274(40): 28528-28536.
292. Glozak MA, Seto E. (2007) Histone deacetylases and cancer. Oncogene; 26(37): 5420-5432.
293. Bolden JE, Peart MJ, Johnstone RW. (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov; 5(9): 769-784.
294. Vaziri H, Dessain SK, Ng EE, Imai SI, Frye RA, Pandita TK, et al. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell; 107(2): 149-159.
295. Afshar G, Murnane JP. (1999) Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2. Gene; 234(1): 161-168.
296. Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP. (2002) SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci USA; 99(21): 13653-13658.
297. Minucci S, Pelicci PG. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer; 6(1): 38-51.
298. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, et al. (2001) Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res; 92(12): 1300-1304.
299. Halkidou K, Cook S, Leung HY, Neal DE, Robson CN. (2004) Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol; 45(3): 382-389.
300. Wilson AJ, Byun DS, Popova N, Murray LB, L’Italien K, Sowa Y, et al. (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem; 281(19): 13548-13558.
301. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, et al. (2005) Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat; 94(1): 11-16.
302. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, et al. (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ; 12(4): 395-404.
303. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, et al. (2005) Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS; 113(4): 264-268.
304. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell; 5(5): 455-463.
305. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, et al. (2004) HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res; 10(20): 6962-6968.
306. Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, et al. (2003) Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun; 309(3): 558-566.
307. de NF, Cerutti J, Morelli C, Califano D, Chiariotti L, Viglietto G, et al. (2002) Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer; 86(6): 917-923.
308. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. (2005) Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia; 19(10): 1751-1759.
309. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, et al. (2006) Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer; 95(8): 1056-1061.
310. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, et al. (2006) Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet; 2(3):e40.
311. Minucci S, Nervi C, Lo CF, Pelicci PG. (2001) Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene; 20(24):3110-3115.
312. Lin RJ, Sternsdorf T, Tini M, Evans RM. (2001) Transcriptional regulation in acute promyelocytic leukemia. Oncogene; 20(49): 7204-7215.
313. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. (2001) Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene; 20(49): 7186-7203.
314. Cress WD, Seto E. (2000) Histone deacetylases, transcriptional control, and cancer. J Cell Physiol; 184(1): 1-16.
315. Cowland JB, Hother C, Gronbaek K. (2007) MicroRNAs and cancer. APMIS; 115(10): 1090-1106.
316. Chuang JC, Jones PA. (2007) Epigenetics and microRNAs. Pediatr Res; 61(5Pt 2):24R-29R.
317. Zhang W, Dahlberg JE, Tam W. (2007) MicroRNAs in tumorigenesis: a primer. Am J Pathol; 171(3): 728-738.
318. Kim SK, Nam JW, Rhee JK, Lee WJ, Zhang BT. (2006) miTarget: microRNA target gene prediction using a support vector machine. BMC Bioinformatics; 7:411.
319. Rajewsky N. (2006) microRNA target predictions in animals. Nat Genet; 38 (Suppl), S8-13.
320. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. (2003) Prediction of mammalian microRNA targets. Cell; 115(7): 787-798.
321. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA; 99(24): 15524-15529.
322. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, et al. (2008) MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA; 105(13): 5166-5171.
323. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA; 102(39): 13944-13949.
324. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. (2006) Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet; 38(9): 1060-1065.
325. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res; 65(21): 9628-9632.
326. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. (2005) c-Mycregulated microRNAs modulate E2F1 expression. Nature; 435(7043): 839-843.
327. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature; 435(7043): 828-833.
328. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. (2008) MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol; 28(17): 5369-5380.
329. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem; 283(2): 1026-1033.
330. Zhu S, Si ML, Wu H, Mo YY. (2007) MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem; 282(19): 14328-14336.
331. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res; 65(16): 7065-7070.
332. Chan JA, Krichevsky AM, Kosik KS. (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res; 65(14): 6029-6033.
333. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA; 104(40): 15805-15810.
334. Mott JL, Kobayashi S, Bronk SF, Gores GJ. (2007) mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene; 26(42): 6133-6140.
335. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, et al. (2006) Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res; 66(24): 11590-11593.
336. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, et al. (2007) Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res; 67(4): 1424-1429.
337. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene; 25(17): 2537-2545.
338. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al. (2007) An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA; 104(50): 19983-19988.
339. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM,Wright T, Hammond SM. (2006) Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev; 20(16): 2202-2207.
340. Saito Y, Jones PA. (2006) Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle; 5(19): 2220-2222.
341. Taganov KD, Boldin MP, Chang KJ, Baltimore D. (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA; 103(33): 12481-12486.
342. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, et al. (2005) Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA; 102(10): 3627-3632.
343. Kluiver J, Poppema S, de JD, Blokzijl T, Harms G, Jacobs S, et al. (2005) BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol; 207(2): 243-249.
344. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. (2004) High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer; 39(2): 167-169.
345. Tam W, Dahlberg JE. (2006) miR-155/BIC as an oncogenic microRNA. Genes Chromosomes Cancer; 45(2): 211-212.
346. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA; 103(7): 2257-2261.
347. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell; 9(3): 189-198.
348. Croce CM. (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet; 10(10): 704-714.
349. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, et al. (2008) MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene; 27(43): 5651-5661.
350. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. (2007) Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J; 26(15): 3699-3708.
351. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, et al. (2005) MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA; 102(50): 18081-18086.
352. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, et al. (2006) A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell; 124(6): 1169-1181.
353. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res; 64(11): 3753-3756.
354. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. (2005) RAS is regulated by the let-7 microRNA family. Cell; 120(5): 635-647.
355. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA; 101(32): 11755-11760.
356. Sinkkonen L, Hugenschmidt T, Berninger P, Gaidatzis D, Mohn F, Artus-Revel CG, et al. (2008) MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells. Nat Struct Mol Biol; 15(3): 259-267.
357. Benetti R, Gonzalo S, Jaco I, Munoz P, Gonzalez S, Schoeftner S, et al. (2008) A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol; 15(3): 268-279.
358. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. (2008) miR-148 targets human DNMT3b protein coding region. RNA; 14(5): 872-877.
359. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA; 101(9): 2999-3004.
360. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, et al. (2007) The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res; 67(4): 1419-1423.